Anti-ILT4 antibodies and antigen-binding fragments
AssigneesMerck Sharp & Dohme Corp., Agenus Inc.
InventorsMilan Blanusa, Barbara Joyce-Shaikh, Andrea Claudia Schuster, Kornelia Schultze, Luis A. Zuniga
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.
Claims18
A polynucleotide comprising a nucleotide sequence encoding a VH, a VL, both a VH and a VL, a heavy chain immunoglobulin, a light chain immunoglobulin, or both a heavy chain and a light chain immunoglobulin of an antibody or antigen-binding fragment thereof that binds human ILT4, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable domain comprising:
- a CDR-H1 having an amino acid sequence of GYYWS (SEQ ID NO:
- 16), a CDR-H2 having an amino acid sequence of EINHSGSTNYNPSLKS (SEQ ID NO:
- 47) or EINHAGSTNYNPSLKS (SEQ ID NO:
- 48), and a CDR-H3 having an amino acid sequence of LPTRWVTTRYFDL (SEQ ID NO:
- 18);
- and a light chain variable domain comprising:
- a CDR-L1 having an amino acid sequence of TGSSSNIGAGYDVH (SEQ ID NO:
- 19), a CDR-L2 having an amino acid sequence of GNSNRPS(SEQ ID NO:
- 49), GQSNRPS(SEQ ID NO:
- 50), GESNRPS(SEQ ID NO:
- 51), GDSNRPS(SEQ ID NO:
- 52), GNANRPS(SEQ ID NO:
- 53), GQANRPS(SEQ ID NO:
- 54), GEANRPS(SEQ ID NO:
- 55), or GDANRPS(SEQ ID NO:
- 56), and a CDR-L3 having an amino acid sequence of QSFDNSLSAYV (SEQ ID NO:
- 21).
A polynucleotide comprising a nucleotide sequence encoding a VH, a VL, both a VH and a VL, a heavy chain immunoglobulin, a light chain immunoglobulin, or both a heavy chain and a light chain immunoglobulin of an antibody or antigen-binding fragment thereof that binds human ILT4, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable domain comprising:
- a CDR-H1 having an amino acid sequence of GYYWS (SEQ ID NO:
- 16), a CDR-H2 having an amino acid sequence of EINHAGSTNYNPSLKS (SEQ ID NO:
- 48), and a CDR-H3 having an amino acid sequence of LPTRWVTTRYFDL (SEQ ID NO:
- 18);
- and a light chain variable domain comprising:
- a CDR-L1 having an amino acid sequence of TGSSSNIGAGYDVH (SEQ ID NO:
- 19), a CDR-L2 having an amino acid sequence of GDSNRPS (SEQ ID NO:
- 52), and a CDR-L3 having an amino acid sequence of QSFDNSLSAYV (SEQ ID NO:
- 21).
Dependencies are inferred from the claim text.